Table 7.

Additional clinical trials in MPM utilizing checkpoint inhibitors

Trial acronym or title	Trial identifier	Treatment	Phase	Primary objective (s)	Completion date	Report status	References
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, and Esophageal Carcinomas, or Pleural Mesotheliomas	NCT03233724	Experimental: 1 (Dose Escalation) Decitabine (DAC) –Tetrahydrouridine (THU) + pembrolizumab at escalating doses Experimental: 2 Dose Expansion DAC-THU + pembrolizumab at the dose established in Arm 1	I/II	Maximum Tolerated Dose (MTD) ORR – to determine if the combination is associated with an ORR which exceeds that of Pembrolizumab alone in patients who have PD-L1 expression of at least 50% and those who do not	Estimated Study Completion Date: December 31, 2026	Running no interim results as yet
ORIGIN Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts	NCT04480372	Cohort 1. NSCLC Cohort 2. Inoperable MPM gemcitabine 1000 mg/m2 on day 1 and day 8 of each cycle (every 3 weeks) and with atezolizumab 1200 mg on day 1 of each cycle (every 3 weeks)	II	ORR	Estimated Primary Completion Date: April 2025 Estimated Study Completion Date: December 2025	Not yet recruiting